# HASUMI ET AL

| |clone| |clonenglml|107|
|---|---|---|---|---|
|clone|1| |0|1₁₀₆|
|PBS|B16/mock|2| |B16/PDGF|
|PDGF-BB|B16/PDGF-BB| |MW|x10-3|
|200-|200-|IB: pTyr| |IB: PDGFRB|
| |Time (days)| |venicie (n-7)|vehicle (n=8)|
|1 500|ST1571 (n=6)| |1₅₀₀|STI571 (n-8)|
|1 400|~-PTK787ISTI571 (n-7)| |1 400|PTK787/STI571 (n=9)|
|1 300| |1 5|1³⁰⁰| |
|200| |5|200|"5#|
|100| |100| | |
| |Time (days)|10|12|14|
|MW x10-3|Sti|STI|STI| |
|250| | |IB pTyr| |
|150| |250| |IB: PDGFRB|
|1.30|6|0.2|14|0.9|
|0|10.6|0.1|0.1|Relative phosph.|
|1.15|0.40|1.15|0.35|0.10|
|Mean relative phosph.| | | | |

FIGURE: Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits Bl6 melanoma tumor growth in vivo. (a) Subconfluent cultures of PAEJPDGFRB cells were stimulated with conditioned media from Bl6/mock or Bl6/PDGF-BB cells for hr on ice (left panels). Alternatively, PAEJPDGFRB cells were incubated for 5 min at 378€ with conditioned medium O increasing amounts of PDGF-BB (right panels). PDGFRB phosphorylation was analyzed by PDGFRB and phospho-tyrosine (pTyr) immunoblotting Of wheat germ agglutinin adsorbed fractions of cell lysates. (b) Bl6/PDGF-BB cells were seeded in [2-well plates and cultured in the presence of vehicle 4),3 AM STIS71 (). AM PTK787 (4j Or 3 UM STIS7] and AM PTK787 (2). Bl6/mock (c) or Bl6/PDGF-BB (d) cells were inoculated subcutaneously to CS7Bl6/J mice When the tumor volume reached 20 mm mice received either p.o. gavage of vehicle 0 ) 100 mg/kglday STIS7L (), 25 mg/kglday PTK787 or 100 mg/kglday STIS7 L and 25 mglkg/day PTK787 (O) Treatment was given for 13 days for mice bearing Bl6/mock tumors () and &days for mice bearing Bl6/PDGF-BB tumors d). Tumor volumes, determined by palpation were followed over time. Results are presented as mean and SE.M Statistical significance was evaluated using a one-way ANOVA followed by post hoc analysis applying the Duncan adjustment: Significance is shown for the last day of treatment: 0.05 compared to vehicle treatment; $_ 0.05 compared to PTK787 treatment; # 0.05 compared to STIS7 treatment: e) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STIS71 (25 mg/100 mg/kg/day; lanes 4 and 5), PTK787 (25 mg/kglday, lanes 6 and 7), STIS7L (100 mg/kg/day, lanes & and 9) or STIS71 (200 mg/kgr day, lanes 10 and 11). PDGFRB was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFRB and phospho-tyrosine (pTyr) immunoblotting: Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1) The ratio between the densitometric analysis of the phosphotyrosine band and the upper; mature PDGFRB band were compared to the first vehicle-treated tumor to obtain the relative receptor phosphorylation: Results transfected with the PDGFRB (PAEJPDGFRB), indicating production of large amount of PDGF-BB. The amount of PDGF-BB released into the conditioned medium was estimated by incubating PAEJPDGFRB cells with either conditioned medium or increasing amounts of PDGF-BB. After 2 days, the Bl6/PDGF-BB cells had released an amount of PDGF into the medium that was in excess of 0.5 ng/ml PDGF-BB. It should be noted that PDGF-BB sticks to both cells and plastic, so this amount is likely to represent underestimation of the production of PDGF-BB.